Abstracts Archive - Page 447 of 2605 - ACR Meeting Abstracts

Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 2277 • ACR Convergence 2023
Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences
Iñigo Rúa-Figueroa¹, Rosana M Quintana², JULIA MARTINEZ BARRIO³, Mercedes García⁴, Maria Galindo-Izquierdo⁵, Lucila Garcia⁶, Jaime Calvo- Alén⁷, Carla Gobbi⁸, Esther Uriarte Isacelaya⁹, Paula Alba⁸, Eva Tomero Muriel¹⁰, Verónica Bellomio¹¹, Mercedes Freire González¹², Susana Roverano⁶, Victor Martinez-Taboada¹³, Analia Patricia Alvarez¹⁴, Eva Salgado-Pérez¹⁵, Cesar Enrique Graf¹⁶, Paloma Vela¹⁷, Cecilia Pisoni¹⁴, Antonio Fernandez-Nebro¹⁸, Valeria Arturi¹⁹, Clara Sanguesa Gomez²⁰, Catalina Gomez¹⁴, Javier Narvaez²¹, Zulema Plaza²², Gregorio Santos Soler²³, Silvia Papasidero²⁴, José Ángel Hernández Beriain²⁵, Raul Paniego⁶, Angela Pecondón²⁶, Maria Celina De La Vega⁶, Oihane Ibarguengoitia-Barrena²⁷, Emma Civit⁸, Gema Bonilla²⁸, Luciana Gonzalez Lucero¹⁴, Vicente Torrente-Segarra²⁹, Maria Victoria Martire⁶, Ana Paula Cacheda³⁰, Rodrigo Aguila Maldonado¹⁴, Maria J. García-Villanueva³¹, Sergio Gordon¹⁴, Clara Moriano Morales³², Marina Micelli⁶, Loreto Horcada³³, Romina Nieto³⁴, Nuria Lozano Rivas³⁵, Gretel Rausch¹⁴, Guillermo Pons-Estel³⁴ and Jose-Maria Pego-Reigosa³⁶, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁵Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁶RELESSAR, CABA, Argentina, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸RELESSAR, Cordoba, Argentina, ⁹Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ¹¹RELESSAR, Tucuman, Argentina, ¹²Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹³Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹⁴Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ¹⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ¹⁶RELESSAR, ENTRE RIOS, Argentina, ¹⁷Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹⁸Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁹RELESSAR, La Plata, Argentina, ²⁰Severo Ochoa Hospital, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Universidad Autónoma de Madrid, Madrid, Spain, ²³Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ²⁴Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²⁵Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Universitario Miguel Servet, Zaragoza, Madrid, Spain, ²⁷Galdakao-Usansolo University Hospital, Bilbao, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁹Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ³⁰Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ³¹Hospital Ramón y Cajal, Madrid, Spain, ³²Rheumatology, Hospital Universitario de León, León, Spain, ³³Hospital de Navarra, Pamplona, Spain, ³⁴RELESSAR, Rosario, Argentina, ³⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multi-organ involvement, associated with substantial morbidity and mortality. A characteristic that distinguishes lupus patients…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1728 • ACR Convergence 2023
A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
Abstract Number: 2271 • ACR Convergence 2023
Longitudinal Changes in Type 1 & Type 2 SLE Activity
Amanda Eudy¹, Jennifer Rogers², Daniel Wojdyla³, Kai Sun², Rebecca Sadun², Mithu Maheswaranathan⁴, Jayanth Doss², Lisa Criscione-Schreiber⁴ and Megan Clowse⁵, ¹Duke University, Raleigh, NC, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: The Type 1 & 2 SLE Model encompass symptoms classically attributed to inflammation, including arthritis, rash, serositis and nephritis (Type 1 SLE), and symptoms…
Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
Abstract Number: 2274 • ACR Convergence 2023
Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN) is a significant comorbidity affecting approximately up to 50-60% of patients with systemic lupus erythematosus (SLE). Complete renal response (CRR) and…
Abstract Number: 2275 • ACR Convergence 2023
Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Anti-Sm autoantibody has been a known specific biomarker of systemic lupus erythematosus (SLE). There have been reports about its correlation with higher disease activity,…
Abstract Number: 1720 • ACR Convergence 2023
Successful Treatment of Rheumatoid Arthritis in Mice Using Cenerimod, a Selective Modulator of the S1P1 Receptor, Demonstrates the Potential Benefits of S1P1 Receptor Immunomodulation for Rheumatic Diseases
Thomas Hoyler, Maxime Bulle, Conrad Wyss, Jeremy Scherer, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Discovery of the essential role of S1P signaling in regulating lymphocyte trafficking led to the development of S1P receptor modulators for the treatment of…
Abstract Number: 1680 • ACR Convergence 2023
What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?
Rieke Alten¹, Juan carlos Nieto-Gonzalez², Peggy Jacques³, Carlomaurizio Montecucco⁴, Robert Moots⁵, Helga Radner⁶, Sebastian Heidenreich⁷, Chiara Whichello⁷, Nicolas Krucien⁷, Monia Zignani⁸, Harald Vonkeman⁹ and Katrien Van Beneden¹⁰, ¹Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ²Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Department of Rheumatology and VIB Inflammation Research Center, University Hospital Ghent, Ghent, Belgium, ⁴Division of Rheumatology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁶Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁷Patient-centred Research, Evidera Inc., London, United Kingdom, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands, ¹⁰Medical Safety, Galapagos NV, Mechelen, Belgium
Background/Purpose: Multiple RA therapies are available that differ in attributes such as mode of administration and benefit-risk profile. Challenging trade-offs are made during treatment selection…
Abstract Number: 1664 • ACR Convergence 2023
Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis
Minghua Wu¹, Jerry Alonso², Julio charles², Brian Skaug², Tingting Mills³, Maureen Mayes² and Shervin Assassi⁴, ¹Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ³Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, ⁴University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: A prominent interferon (IFN) activation signature has been observed at the peripheral blood and end-organ levels in systemic sclerosis (SSc). However, the mechanisms by…
Abstract Number: 1666 • ACR Convergence 2023
TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin/Basement Membrane Ligand-Receptor Signaling
Javier Rangel-Moreno¹, Maria de la Luz Garcia-Hernandez², Qingfu Xu³ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: : We recently described TNF-transgenic mice as a novel model of pulmonary hypertension (PH) and have shown that they express altered endothelial and mesenchymal…
Abstract Number: 1245 • ACR Convergence 2023
Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease
Sara Stern¹, Matthew Basiaga², Linda Amoafo¹, Seunghee Cha³, Akaluck Thatayatikom⁴, Erin Treemarcki¹, Rachel Randell⁵, Brian Dizon⁶, Jamie Diianni⁷, Sharon Tiger⁸, Janet Orrock⁹, Simone Appenzeller¹⁰, Cuoghi Edens¹¹ and Scott Lieberman¹², ¹University of Utah School of Medicine, Salt Lake City, UT, ²Mayo Clinic, Rochester, MN, ³Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL, ⁴AdventHealth for Children, Orlando, FL, Orlando, FL, ⁵Duke University School of Medicine, Durham, NC, ⁶National Institute of Arthritis and Musculoskelatal and Skin Diseases, Bethesda, MD, ⁷Childhood Arthritis and Rheumatology Research Alliance (CARRA), Washington, DC, ⁸Childhood Arthritis and Rheumatology Research Alliance (CARRA), Beltsville, MD, ⁹The University of Texas at Austin Dell Medical School, Austin, TX, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Chicago, Chicago, IL, ¹²University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: There are no widely accepted diagnostic or classification criteria for childhood Sjögren's disease (cSjD). To address the urgent need for consensus, the Childhood Arthritis…
Abstract Number: 1667 • ACR Convergence 2023
Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry
Minrui Liang¹, Aleix Rius Rigau², yi-nan Li¹ and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie (DZI), FAU Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a prototypical collagen-vascular disease with prominent vasculopathy. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular dysregulation…
Abstract Number: 1679 • ACR Convergence 2023
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Kazuhiro Yokota¹, Yoshimi Aizaki², Takuma Tsuzuki Wada¹, Hiroshi Kajiyama¹, Yasuto Araki², Hiroaki Yazawa², Yuji Akiyama² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: We have previously demonstrated that a combination of TNF-a and IL-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].